Azelaic acid 15% gel for treatment of rosacea

References

• Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J. Am. Acad. Dermatol.51, 327–341 (2004).
   PubMed Web of Science ®Google Scholar
• Powell FC. Rosacea. N. Engl. J. Med.352, 793–803 (2005).
   PubMed Web of Science ®Google Scholar
• Berg M, Liden S. An epidemiological study of rosacea. Acta Derm. Venereol.69, 419–423 (1989).
   PubMed Web of Science ®Google Scholar
• Wilkin J, Dahl M, Detmar M et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J. Am. Acad. Dermatol.46, 584–587 (2002).
   PubMed Web of Science ®Google Scholar
• Wilkin J, Dahl M, Detmar M et al. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J. Am. Acad. Dermatol.50, 907–912 (2004).
   PubMed Web of Science ®Google Scholar
• Blount BW, Pelletier AL. Rosacea: a common, yet commonly overlooked, condition. Am. Fam. Physician66, 435–440 (2002).
   PubMed Web of Science ®Google Scholar
• Fleischer A, Suephy C. The face and mind evaluation study: an examination of the efficacy of rosacea treatment using physician ratings and patients’ self-reported quality of life. J. Drugs Dermatol.4, 585–590 (2005).
   PubMedGoogle Scholar
• Miyachi Y, Imamura S, Niwa Y. Anti-oxidant action of metronidazole: a possible mechanism of action in rosacea. Br. J. Dermatol.114, 231–234 (1986).
   PubMed Web of Science ®Google Scholar
• Miyachi Y. Potential antioxidant mechanisms of action for metronidazole: implications for rosacea management. Adv. Ther.18, 237–243 (2001).
   PubMed Web of Science ®Google Scholar
• Millikan L. The proposed inflammatory pathophysiology of rosacea: implications for treatment. Skinmed2, 43–47 (2003).
   PubMedGoogle Scholar
• Passi S, Picardo M, Zompetta C, De Luca C, Breathnach AS, Nazzaro-Porro M. The oxyradical-scavenging activity of azelaic acid in biological systems. Free Radic. Res. Commun.15, 17–28 (1991).
   PubMed Web of Science ®Google Scholar
• Akamatsu H, Komura J, Asada Y, Miyachi Y, Niwa Y. Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated diseases. Arch. Dermatol. Res.283, 162–166 (1991).
   PubMed Web of Science ®Google Scholar
• Jones D. Reactive oxygen species and rosacea. Cutis74(Suppl. 3), 17–20, 3234 (2004).
   PubMed Web of Science ®Google Scholar
• Dahl MV. Pathogenesis of rosacea. Adv. Dermatol.17, 29–45 (2001).
   PubMedGoogle Scholar
• Nielsen PG. Treatment of rosacea with 1% metronidazole cream. A double-blind study. Br. J. Dermatol.108, 327–332 (1983).
   PubMed Web of Science ®Google Scholar
• Bikowski JB, Goldman MP. Rosacea: where are we now? J. Drugs Dermatol.3, 251–261 (2004).
   PubMedGoogle Scholar
• Wolf JE Jr. The role of topical metronidazole in the treatment of rosacea. Cutis73(Suppl. 1), 19–28 (2004).
   PubMedGoogle Scholar
• Ziel K, Yelverton CB, Balkrishnan R, Feldman SR. Cumulative irritation potential of metronidazole gel compared to azelaic acid gel after repeated applications to healthy skin. J. Drugs Dermatol.4, 727–731 (2005).
   PubMedGoogle Scholar
• Del Rosso JQ. Medical treatment of rosacea with emphasis on topical therapies. Expert Opin. Pharmacother.5, 5–13 (2004).
   PubMed Web of Science ®Google Scholar
• No authors listed. Azelaic acid (Finacea) for rosacea. Med. Lett. Drugs Ther.45, 76–77 (2003).
   PubMed Web of Science ®Google Scholar
• Van Landuyt H, Joubert-Lequain I, Humbert P et al. Treatment of rosacea. Clonidine (0.075 mg per day) versus placebo (initial results). Ann. Dermatol. Venereol.124, 729 (1997).
   PubMed Web of Science ®Google Scholar
• Grosshans E, Michel C, Arcade B, Cribier B. Rilmenidine in rosacea: a double-blind study versus placebo. Ann. Dermatol. Venereol.124, 687–691 (1997).
   PubMed Web of Science ®Google Scholar
• Wilkin JK. Effect of nadolol on flushing reactions in rosacea. J. Am. Acad. Dermatol.20, 202–205 (1989).
   PubMed Web of Science ®Google Scholar
• Detmar M. The role of VEGF and thrombospondins in skin angiogenesis. J. Dermatol. Sci.24(Suppl. 1), S78–S84 (2000).
   PubMed Web of Science ®Google Scholar
• Kocak M, Yagli S, Vahapoglu G, Eksioglu M. Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. A randomized double-blind placebo-controlled study. Dermatology205, 265–270 (2002).
   PubMed Web of Science ®Google Scholar
• Clyti E, Sayavong K, Chanthavisouk K. Demodecidosis in a patient infected by HIV: successful treatment with ivermectin. Ann. Dermatol. Venereol.132, 459–461 (2005).
   PubMed Web of Science ®Google Scholar
• Forton F, Germaux MA, Brasseur T et al. Demodicosis and rosacea: epidemiology and significance in daily dermatologic practice. J. Am. Acad. Dermatol.52, 74–87 (2005).
   PubMed Web of Science ®Google Scholar
• Nazzaro-Porro M, Passi S. Effetto degli acidi dicarbossilici in alcune dermatosi pigmentarie. G. Ital. Dermatol.113, 401–404 (1978).
   Google Scholar
• Nazzaro-Porro M, Passi S, Picardo M, Breathnach A, Clayton R, Zina G. Beneficial effect of 15% azelaic acid cream on acne vulgaris. Br. J. Dermatol.109, 45–48 (1983).
   PubMed Web of Science ®Google Scholar
• Guttman C. Rosacea relief: Finacea represents FDA’s first rosacea Tx approval in decade. Dermatol. Times February 1 (2003).
   Google Scholar
• Draelos ZD, Graupe K. A new topical formulation for the treatment of mild to moderate papulopustular rosacea: azelaic acid 15% gel. Proceedings of the American Academy of Dermatology 61st Annual Meeting. CA, USA, Poster 49 (2003).
   Google Scholar
• Topert M, Rach P, Siegmund F. Pharmacology and toxicology of azelaic acid. Acta Derm. Venereol.143(Suppl.), 14–19 (1989).
   Google Scholar
• Picardo M, Passi S, Sirianni MC et al. Activity of azelaic acid on cultures of lymphoma- and leukemia-derived cell lines, normal resting and stimulated lymphocytes and 3T3 fibroblasts. Biochem. Pharmacol.34, 1653–1658 (1985).
   PubMed Web of Science ®Google Scholar
• Leibl H, Stingl G, Pehamberger H, Korschan H, Konrad K, Wolff K. Inhibition of DNA synthesis of melanoma cells by azelaic acid. J. Invest. Dermatol.85, 417–422 (1985).
   PubMed Web of Science ®Google Scholar
• Schallreuter KU, Wood JM. Azelaic acid as a competitive inhibitor of thioredoxin reductase in human melanoma cells. Cancer Lett.36, 297–305 (1987).
   PubMed Web of Science ®Google Scholar
• Breathnach AS. Azelaic acid: potential as a general antitumoural agent. Med. Hypotheses52, 221–226 (1999).
   PubMed Web of Science ®Google Scholar
• Nazzaro-Porro M. Azelaic acid. J. Am. Acad. Dermatol.17, 1033–1041 (1987).
   PubMed Web of Science ®Google Scholar
• Brasch J, Christophers E. Azelaic acid has antimycotic properties in vitro. Dermatology186, 55–58 (1993).
   PubMed Web of Science ®Google Scholar
• Leeming JP, Holland KT, Bojar RA. The in vitro antimicrobial effect of azelaic acid. Br. J. Dermatol.115, 551–556 (1986).
   PubMed Web of Science ®Google Scholar
• Tauber U, Weiss C, Matthes H. Percutaneous absorption of azelaic acid in humans. Exp. Dermatol.1, 176–179 (1992).
   PubMedGoogle Scholar
• Bojar RA, Cutliffe AG, Graupe K, Cunliffe WJ, Holland KT. Follicular concentrations of azelaic acid after a single topical application. Br. J. Dermatol.129, 399–402 (1993).
   PubMed Web of Science ®Google Scholar
• Product information file, Finacea® (2003).
   Google Scholar
• Passi S, Picardo M, Mingrone G, Breathnach AS, Nazzaro-Porro M. Azelaic acid–biochemistry and metabolism. Acta Derm. Venereol.143(Suppl.), 8–13 (1989).
   Google Scholar
• Passi S, Picardo M, De Luca C, Breathnach AS, Nazzaro-Porro M. Scavenging activity of azelaic acid on hydroxyl radicals “in vitro.” Free Radic. Res. Commun.1, 329–338 (1991).
   Google Scholar
• Nazzaro-Porro M, Passi S, Picardo M, Balus L, Breathnach AS. Azelaic acid in rosacea? G. Ital. Dermatol. Venerol.126, 19–27 (1991).
   Google Scholar
• Carmichael AJ, Marks R, Graupe KA, Zaumseil RP. Topical azelaic acid in the treatment of rosacea. J. Dermatol. Treat.4(Suppl. 1), S19–S22 (1993).
   Google Scholar
• Bjerke R, Fryand O, Graupe K. Double-blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo-pustular rosacea. Acta Derm. Venereol.79, 456–459 (1999).
   PubMed Web of Science ®Google Scholar
• Maddin S. A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. J. Am. Acad. Dermatol.40, 961–965 (1999).
   PubMed Web of Science ®Google Scholar
• Data on file. Intendis.
   Google Scholar
• Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized Phase III studies. J. Am. Acad. Dermatol.48, 836–845 (2003).
   PubMed Web of Science ®Google Scholar
• Elewski BE, Fleischer AB Jr, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch. Dermatol.139, 1444–1450 (2003).
   PubMedGoogle Scholar
• Wolf JE, Kerrouche N, Arsonnaud S. Efficacy and safety of once-daily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea. Cutis77(Suppl. 4), 3–11 (2006).
   PubMed Web of Science ®Google Scholar
• Draelos ZD. Noxious sensory perceptions in patients with mild to moderate rosacea treated with azelaic acid 15% gel. Cutis74, 257–260 (2004).
   PubMed Web of Science ®Google Scholar